Payment overview · 2025
General Payments
$538.26
29 reported records · 17 companies
Healthcare provider profile · identity verified
Saira Jamal, M.D
Allopathic & Osteopathic Physicians|Family Medicine · FLOWER MOUND, TX · NPI 1760496004
Verified facts
What the public records show
CMS Open Payments records show Saira Jamal, M.D received $538.26 in general payments during 2025 across 29 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $100.13 | 18.6% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $56.88 | 10.6% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $54.68 | 10.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $38.86 | 7.2% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $34.63 | 6.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $33.70 | 6.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.16 | 5.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.16 | 5.2% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $26.91 | 5.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.96 | 3.9% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $20.05 | 3.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.91 | 3.3% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $16.22 | 3.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.00 | 3.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.39 | 2.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.87 | 2.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.75 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $538.26 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $54.68 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $52.57 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $38.86 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $34.63 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.01 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $33.70 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $33.38 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.16 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.16 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $28.16 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $28.16 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $26.91 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $22.87 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 101 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
101 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 462 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 433 | 116 |
| Montelukast Sodium | Montelukast Sodium | 406 | 126 |
| Atorvastatin Calcium | Atorvastatin Calcium | 348 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 336 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 251 | 69 |
| Lisinopril | Lisinopril | 227 | 56 |
| Metformin Hcl | Metformin Hcl | 197 | 64 |
| Gabapentin | Gabapentin | 178 | 55 |
| Losartan Potassium | Losartan Potassium | 174 | 53 |
| Omeprazole | Omeprazole | 173 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 144 | 35 |
| Carvedilol | Carvedilol | 142 | 42 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 137 | 51 |
| Potassium Chloride | Potassium Chloride | 135 | 36 |
| Furosemide | Furosemide | 131 | 41 |
| Trazodone Hcl | Trazodone Hcl | 128 | 34 |
| Donepezil Hcl | Donepezil Hcl | 127 | 29 |
| Valsartan | Valsartan | 127 | 38 |
| Famotidine | Famotidine | 120 | 36 |
| Alendronate Sodium | Alendronate Sodium | 113 | 27 |
| Mounjaro | Tirzepatide | 101 | 15 |
| Azelastine Hcl | Azelastine Hcl | 97 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 28 |
| Eliquis | Apixaban | 90 | 20 |
| Glimepiride | Glimepiride | 88 | 26 |
| Ezetimibe | Ezetimibe | 87 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 86 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 35 |
| Buspirone Hcl | Buspirone Hcl | 84 | 28 |
| Memantine Hcl | Memantine Hcl | 80 | 23 |
| Tramadol Hcl | Tramadol Hcl | 80 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | 19 |
| Sertraline Hcl | Sertraline Hcl | 73 | 21 |
| Simvastatin | Simvastatin | 73 | 20 |
| Mirtazapine | Mirtazapine | 70 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 19 |
| Eszopiclone | Eszopiclone | 63 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 16 |
| Alprazolam | Alprazolam | 57 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | suppressed |
| Fenofibrate | Fenofibrate | 51 | 13 |
| Clonazepam | Clonazepam | 50 | 13 |
| Myrbetriq | Mirabegron | 50 | 11 |
| Liothyronine Sodium | Liothyronine Sodium | 49 | suppressed |
| Topiramate | Topiramate | 49 | 16 |
| Meloxicam | Meloxicam | 47 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 24 |
| Metformin Hcl Er | Metformin Hcl | 43 | suppressed |
| Synthroid | Levothyroxine Sodium | 43 | 11 |
| Cefuroxime | Cefuroxime Axetil | 38 | 33 |
| Ozempic | Semaglutide | 38 | suppressed |
| Telmisartan | Telmisartan | 37 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 11 |
| Azithromycin | Azithromycin | 35 | 33 |
| Allopurinol | Allopurinol | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Sucralfate | Sucralfate | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 24 |
| Jardiance | Empagliflozin | 31 | suppressed |
| Prednisone | Prednisone | 30 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | 17 |
| Estradiol | Estradiol | 28 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | 14 |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 18 |
| Temazepam | Temazepam | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Nateglinide | Nateglinide | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 16 |
| Cephalexin | Cephalexin | 16 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Alprazolam Er | Alprazolam | 15 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 11 |
| Folic Acid | Folic Acid | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $538.26 · 29 records | AstraZeneca Pharmaceuticals LP | AREXVY, Auvelity, BREZTRI, FARXIGA, Flector, GEMTESA, Heplisav-B, INSPIRE, KISUNLA, Korlym, Leqembi, Licart, MOUNJARO, PROCLAIM, QULIPTA, REPATHA, REXULTI, SHINGRIX, Tirosint, UBRELVY, VYEPTI, Wegovy, XIFAXAN, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error